Targeted Sequencing of Plasmacytoid Urothelial Carcinoma Reveals Frequent Tert Promoter Mutations Publisher Pubmed



Palsgrove DN¹ ; Taheri D^{1, 2} ; Springer SU^{3, 4} ; Cowan M¹ ; Guner G¹ ; Mendoza Rodriguez MA¹ ; Rodriguez Pena MDC^{1, 5} ; Wang Y⁴ ; Kinde I⁴ ; Ricardo BFP¹ ; Cunha I⁶ ; Fujita K⁷ ; Ertoy D⁸ ; Kinzler KW^{3, 4} Show All Authors Show Affiliations
Source: Human Pathology Published:2019

Abstract

Activating mutations in the promoter of the telomerase reverse transcriptase (TERT) gene are the most common genetic alterations in urothelial carcinoma (UC) of the bladder and upper urinary tract. Although the cadherin 1 (CDH1) gene is commonly mutated in the clinically aggressive plasmacytoid variant of urothelial carcinoma (PUC), little is known about their TERT promoter mutation status. A retrospective search of our archives for PUC and UC with plasmacytoid and/or signet ring cell features (2007-2014) was performed. Ten specimens from 10 patients had archived material available for DNA analysis and were included in the study. Intratumoral areas of nonplasmacytoid histology were also evaluated when present. Samples were analyzed for TERT promoter mutations with Safe-SeqS, a sequencing error-reduction technology, and sequenced using a targeted panel of the 10 most commonly mutated genes in bladder cancer on the Illumina MiSeq platform. TERT promoter mutations were detected in specimens with pure and focal plasmacytoid features (6/10). Similar to conventional UC, the predominant mutation identified was g.1295228C>T. In heterogeneous tumors with focal variant histology, concordant mutations were found in plasmacytoid and corresponding conventional, glandular, or sarcomatoid areas. Co-occurring mutations in tumor protein p53 (TP53, 2 cases) and kirsten rat sarcoma (KRAS) viral proto-oncogene (1 case) were also detected. TERT promoter mutations are frequently present in PUC, which provides further evidence that TERT promoter mutations are common events in bladder cancer, regardless of histologic subtype, and supports their inclusion in any liquid biopsy assay for bladder cancer. © 2018 Elsevier Inc.